Raymond James Financial Downgrades Tvardi Therapeutics (NASDAQ:TVRD) to Market Perform

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by investment analysts at Raymond James Financial from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, MarketBeat reports.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday. Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, BTIG Research lowered their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a report on Monday. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Price Performance

Shares of Tvardi Therapeutics stock opened at $7.00 on Tuesday. The company has a 50-day moving average price of $31.25. Tvardi Therapeutics has a fifty-two week low of $5.65 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth about $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Finally, Bank of America Corp DE purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at about $399,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.